• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

    11.02 -0.24 (-2.09%)
    Delayed Quote Updated: 10:22 AM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 327,418
    Open 11.40
    Bid (Size) 11.03 (500)
    Ask (Size) 11.05 (600)
    Prev. Close 11.26
    Today's Range 10.75 - 11.40
    52wk Range 7.235 - 25.77
    Shares Outstanding 49,383,711
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    These stocks are moving in today's after hours session ↗
    Via Chartmill

    Performance

    52-Week Range 57.2% below 52-week high
    11.02
    7.2452W Low 25.7752W High
    1 Week 10.1% below 1-week high
    11.071W Low 12.261W High

    Monte Rosa Therapeutics, Inc. - Common Stock (GLUE) traded between $7.24 and $25.77 over the past 52 weeks and last traded at $11.02, 57.2% below its 52-week high. Over the past week it ranged between $11.07 and $12.26.

    Past 12 Months
    -6.3%
    -23.0%
    -54.5%
    -35.5%
    -28.0%
    +47.0%
    1W -$0.75
    1M -$3.29
    3M -$13.19
    6M -$6.07
    YTD -$4.29
    1Y +$3.52

    GLUE was +47.0% over the past year, -35.5% over six months, -28.0% year to date, -6.3% in the last week.

    12 Months vs Market
    GLUE
    +47.0%
    DIA
    +10.2%
    SPY
    +15.5%
    QQQ
    +25.0%
    IWM
    +16.7%

    Over the past 12 months GLUE returned +47.0% versus DIA (Dow) +10.2%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +25.0% and IWM (Russell 2000) +16.7%.

    Volume & Liquidity 0.25× 3-mo avg
    Today 327,418 3-mo avg 1.3M
    1W
    1.2M
    1M
    1.2M
    3M
    1.3M
    6M
    1.2M
    YTD
    1.3M
    1Y
    1.3M

    GLUE most recently traded 327,418 shares against a 3-month average daily volume of 1.3M.

    More News

    Read More
    News headline image
    Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics (NASDAQ:GLUE) Beats Q2 Revenue Estimates but Posts Wider Loss ↗
    Via Chartmill
    Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts ↗
    Via Chartmill
    News headline image
    Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Gapping stocks in Friday's session ↗
    Via Chartmill
    Friday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher ↗
    Via MarketBeat

    Frequently Asked Questions

    Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?
    Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?
    The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market
    What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?
    The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 11.02
    When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?
    The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 10/02/26 10:22 AM ET
    What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?
    The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 544.44M
    How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?
    Monte Rosa Therapeutics, Inc. - Common Stock has 544M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.